Review





Similar Products

snx 482  (Alomone Labs)
94
Alomone Labs snx 482
Snx 482, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/snx 482/product/Alomone Labs
Average 94 stars, based on 1 article reviews
snx 482 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
cav2 3 blocker snx482  (Alomone Labs)
94
Alomone Labs cav2 3 blocker snx482
A Graphical abstract illustrating working hypothesis on actions of dopamine tone on spontaneous glutamate release. B Graphical depiction showing experimental paradigm for rotundine (200 nM or 10 μM) or levosulpride perfusions. C Representative mEPSC traces for rotundine (200 nM or 10 μM) or levosulpride perfusions. [Treatment duration: acute perfusion (seconds to minutes)]. D Amplitudes of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions. (Baseline, n = 7, Mean = 15.42 ± 1.36 S.E.M.; 200 nM Rotundine perfusion, n = 7, Mean = 16.46 ± 2.05 S.E.M.; Baseline, n = 13, Mean = 14.34 ± 0.97 S.E.M.; 10 μM Rotundine Perfusion, n = 13, Mean = 14.45 ± 2.33 S.E.M.; Baseline, n = 10, Mean = 16.74 ± 1.61 S.E.M.; 10 μM Levosulpride Perfusion, n = 10, Mean = 16.04 ± 2.30 S.E.M.). E Frequency of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions. (Baseline, n = 7, Mean = 5.72 ± 1.37 S.E.M.; 200 nM Rotundine perfusion, n = 7, Mean = 6.48 ± 1.22 S.E.M.; Baseline, n = 13, Mean = 4.15 ± 1.00 S.E.M.; 10 μM Rotundine Perfusion, n = 13, Mean = 6.48 ± 1.51 S.E.M.; Baseline, n = 10, Mean = 4.23 ± 1.51 S.E.M.; 10 μM Levosulpride Perfusion, n = 10, Mean = 5.96 ± 1.40 S.E.M.). F Graphical abstract illustrating Agatoxin, conotoxin and <t>SNX482</t> (VGCC cocktail) blocking presynaptic VGCCs. G Graphical depiction showing experimental paradigm for rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail [Treatment duration: acute perfusion (seconds to minutes)]. H Representative mEPSC traces for rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail. I Amplitudes of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail. (Baseline, n = 8, Mean = 15.82 ± 1.32 S.E.M.; 200 nM Rotundine perfusion, n = 8, Mean = 14.99 ± 1.33 S.E.M.; Baseline, n = 11, Mean = 12.74 ± 0.95 S.E.M.; 10 μM Rotundine Perfusion, n = 11, Mean = 12.9 ± 0.68 S.E.M. ; Baseline, n = 16, Mean = 14.91 ± 1.08 S.E.M.; 10 μM Levosulpride Perfusion, n = 16, Mean = 14.86 ± 1.30 S.E.M.). J Frequency of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail. (Baseline, n = 8, Mean = 5.19 ± 0.91 S.E.M.; 200 nM Rotundine perfusion, n = 8, Mean = 4.86 ± 0.60 S.E.M.; Baseline, n = 11, Mean = 3.38 ± 0.72 S.E.M.; 10 μM Rotundine Perfusion, n = 11, Mean = 3.21 ± 0.67 S.E.M. ; Baseline, n = 16, Mean = 4.95 ± 0.97 S.E.M.; 10 μM Levosulpride Perfusion, n = 16, Mean = 5.53 ± 1.33 S.E.M.). K Graphical depiction illustrating myristylation of ct-GRK2 to scavenge Gβγ subunit. L Graphical depiction showing experimental paradigm for Gβγ scavenging. M Representative mEPSC traces for pFUW (control) and myr ct-GRK2 groups at baseline and after levosulpride perfusion [Treatment duration: acute perfusion (seconds to minutes)]. N Amplitudes of mEPSC events in pFUW (control) and myr ct-GRK2 groups at baseline and after levosulpride perfusion. (Baseline-pFUW, n = 9, Mean = 14.66 ± 0.79 S.E.M.; Levosulpride Perfusion-pFUW, n = 9, Mean = 16.62 ± 1.87 S.E.M.; Baseline- myr ct-GRK2, n = 11, Mean = 18.28 ± 1.08 S.E.M.; Levosulpride Perfusion-myr ct-GRK2, n = 11, Mean = 19.3 ± 1.24 S.E.M.). O Frequency of mEPSC events in pFUW (control) and myr ct-GRK2 groups at baseline and after levosulpride perfusion. (Baseline-pFUW, n = 8, Mean = 2.43 ± 0.66 S.E.M.; Levosulpride Perfusion-pFUW, n = 8, Mean = 4.16 ± 1.01 S.E.M.; Baseline- myr ct-GRK2, n = 11, Mean = 4.60 ± 0.605 S.E.M.; Levosulpride Perfusion-myr ct-GRK2, n = 11, Mean = 4.88 ± 0.608 S.E.M.).
Cav2 3 Blocker Snx482, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cav2 3 blocker snx482/product/Alomone Labs
Average 94 stars, based on 1 article reviews
cav2 3 blocker snx482 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
snx 2112  (Selleck Chemicals)
93
Selleck Chemicals snx 2112
A Graphical abstract illustrating working hypothesis on actions of dopamine tone on spontaneous glutamate release. B Graphical depiction showing experimental paradigm for rotundine (200 nM or 10 μM) or levosulpride perfusions. C Representative mEPSC traces for rotundine (200 nM or 10 μM) or levosulpride perfusions. [Treatment duration: acute perfusion (seconds to minutes)]. D Amplitudes of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions. (Baseline, n = 7, Mean = 15.42 ± 1.36 S.E.M.; 200 nM Rotundine perfusion, n = 7, Mean = 16.46 ± 2.05 S.E.M.; Baseline, n = 13, Mean = 14.34 ± 0.97 S.E.M.; 10 μM Rotundine Perfusion, n = 13, Mean = 14.45 ± 2.33 S.E.M.; Baseline, n = 10, Mean = 16.74 ± 1.61 S.E.M.; 10 μM Levosulpride Perfusion, n = 10, Mean = 16.04 ± 2.30 S.E.M.). E Frequency of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions. (Baseline, n = 7, Mean = 5.72 ± 1.37 S.E.M.; 200 nM Rotundine perfusion, n = 7, Mean = 6.48 ± 1.22 S.E.M.; Baseline, n = 13, Mean = 4.15 ± 1.00 S.E.M.; 10 μM Rotundine Perfusion, n = 13, Mean = 6.48 ± 1.51 S.E.M.; Baseline, n = 10, Mean = 4.23 ± 1.51 S.E.M.; 10 μM Levosulpride Perfusion, n = 10, Mean = 5.96 ± 1.40 S.E.M.). F Graphical abstract illustrating Agatoxin, conotoxin and <t>SNX482</t> (VGCC cocktail) blocking presynaptic VGCCs. G Graphical depiction showing experimental paradigm for rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail [Treatment duration: acute perfusion (seconds to minutes)]. H Representative mEPSC traces for rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail. I Amplitudes of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail. (Baseline, n = 8, Mean = 15.82 ± 1.32 S.E.M.; 200 nM Rotundine perfusion, n = 8, Mean = 14.99 ± 1.33 S.E.M.; Baseline, n = 11, Mean = 12.74 ± 0.95 S.E.M.; 10 μM Rotundine Perfusion, n = 11, Mean = 12.9 ± 0.68 S.E.M. ; Baseline, n = 16, Mean = 14.91 ± 1.08 S.E.M.; 10 μM Levosulpride Perfusion, n = 16, Mean = 14.86 ± 1.30 S.E.M.). J Frequency of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail. (Baseline, n = 8, Mean = 5.19 ± 0.91 S.E.M.; 200 nM Rotundine perfusion, n = 8, Mean = 4.86 ± 0.60 S.E.M.; Baseline, n = 11, Mean = 3.38 ± 0.72 S.E.M.; 10 μM Rotundine Perfusion, n = 11, Mean = 3.21 ± 0.67 S.E.M. ; Baseline, n = 16, Mean = 4.95 ± 0.97 S.E.M.; 10 μM Levosulpride Perfusion, n = 16, Mean = 5.53 ± 1.33 S.E.M.). K Graphical depiction illustrating myristylation of ct-GRK2 to scavenge Gβγ subunit. L Graphical depiction showing experimental paradigm for Gβγ scavenging. M Representative mEPSC traces for pFUW (control) and myr ct-GRK2 groups at baseline and after levosulpride perfusion [Treatment duration: acute perfusion (seconds to minutes)]. N Amplitudes of mEPSC events in pFUW (control) and myr ct-GRK2 groups at baseline and after levosulpride perfusion. (Baseline-pFUW, n = 9, Mean = 14.66 ± 0.79 S.E.M.; Levosulpride Perfusion-pFUW, n = 9, Mean = 16.62 ± 1.87 S.E.M.; Baseline- myr ct-GRK2, n = 11, Mean = 18.28 ± 1.08 S.E.M.; Levosulpride Perfusion-myr ct-GRK2, n = 11, Mean = 19.3 ± 1.24 S.E.M.). O Frequency of mEPSC events in pFUW (control) and myr ct-GRK2 groups at baseline and after levosulpride perfusion. (Baseline-pFUW, n = 8, Mean = 2.43 ± 0.66 S.E.M.; Levosulpride Perfusion-pFUW, n = 8, Mean = 4.16 ± 1.01 S.E.M.; Baseline- myr ct-GRK2, n = 11, Mean = 4.60 ± 0.605 S.E.M.; Levosulpride Perfusion-myr ct-GRK2, n = 11, Mean = 4.88 ± 0.608 S.E.M.).
Snx 2112, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/snx 2112/product/Selleck Chemicals
Average 93 stars, based on 1 article reviews
snx 2112 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
ω theraphotoxin hg1a  (Alomone Labs)
94
Alomone Labs ω theraphotoxin hg1a
A Graphical abstract illustrating working hypothesis on actions of dopamine tone on spontaneous glutamate release. B Graphical depiction showing experimental paradigm for rotundine (200 nM or 10 μM) or levosulpride perfusions. C Representative mEPSC traces for rotundine (200 nM or 10 μM) or levosulpride perfusions. [Treatment duration: acute perfusion (seconds to minutes)]. D Amplitudes of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions. (Baseline, n = 7, Mean = 15.42 ± 1.36 S.E.M.; 200 nM Rotundine perfusion, n = 7, Mean = 16.46 ± 2.05 S.E.M.; Baseline, n = 13, Mean = 14.34 ± 0.97 S.E.M.; 10 μM Rotundine Perfusion, n = 13, Mean = 14.45 ± 2.33 S.E.M.; Baseline, n = 10, Mean = 16.74 ± 1.61 S.E.M.; 10 μM Levosulpride Perfusion, n = 10, Mean = 16.04 ± 2.30 S.E.M.). E Frequency of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions. (Baseline, n = 7, Mean = 5.72 ± 1.37 S.E.M.; 200 nM Rotundine perfusion, n = 7, Mean = 6.48 ± 1.22 S.E.M.; Baseline, n = 13, Mean = 4.15 ± 1.00 S.E.M.; 10 μM Rotundine Perfusion, n = 13, Mean = 6.48 ± 1.51 S.E.M.; Baseline, n = 10, Mean = 4.23 ± 1.51 S.E.M.; 10 μM Levosulpride Perfusion, n = 10, Mean = 5.96 ± 1.40 S.E.M.). F Graphical abstract illustrating Agatoxin, conotoxin and <t>SNX482</t> (VGCC cocktail) blocking presynaptic VGCCs. G Graphical depiction showing experimental paradigm for rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail [Treatment duration: acute perfusion (seconds to minutes)]. H Representative mEPSC traces for rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail. I Amplitudes of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail. (Baseline, n = 8, Mean = 15.82 ± 1.32 S.E.M.; 200 nM Rotundine perfusion, n = 8, Mean = 14.99 ± 1.33 S.E.M.; Baseline, n = 11, Mean = 12.74 ± 0.95 S.E.M.; 10 μM Rotundine Perfusion, n = 11, Mean = 12.9 ± 0.68 S.E.M. ; Baseline, n = 16, Mean = 14.91 ± 1.08 S.E.M.; 10 μM Levosulpride Perfusion, n = 16, Mean = 14.86 ± 1.30 S.E.M.). J Frequency of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail. (Baseline, n = 8, Mean = 5.19 ± 0.91 S.E.M.; 200 nM Rotundine perfusion, n = 8, Mean = 4.86 ± 0.60 S.E.M.; Baseline, n = 11, Mean = 3.38 ± 0.72 S.E.M.; 10 μM Rotundine Perfusion, n = 11, Mean = 3.21 ± 0.67 S.E.M. ; Baseline, n = 16, Mean = 4.95 ± 0.97 S.E.M.; 10 μM Levosulpride Perfusion, n = 16, Mean = 5.53 ± 1.33 S.E.M.). K Graphical depiction illustrating myristylation of ct-GRK2 to scavenge Gβγ subunit. L Graphical depiction showing experimental paradigm for Gβγ scavenging. M Representative mEPSC traces for pFUW (control) and myr ct-GRK2 groups at baseline and after levosulpride perfusion [Treatment duration: acute perfusion (seconds to minutes)]. N Amplitudes of mEPSC events in pFUW (control) and myr ct-GRK2 groups at baseline and after levosulpride perfusion. (Baseline-pFUW, n = 9, Mean = 14.66 ± 0.79 S.E.M.; Levosulpride Perfusion-pFUW, n = 9, Mean = 16.62 ± 1.87 S.E.M.; Baseline- myr ct-GRK2, n = 11, Mean = 18.28 ± 1.08 S.E.M.; Levosulpride Perfusion-myr ct-GRK2, n = 11, Mean = 19.3 ± 1.24 S.E.M.). O Frequency of mEPSC events in pFUW (control) and myr ct-GRK2 groups at baseline and after levosulpride perfusion. (Baseline-pFUW, n = 8, Mean = 2.43 ± 0.66 S.E.M.; Levosulpride Perfusion-pFUW, n = 8, Mean = 4.16 ± 1.01 S.E.M.; Baseline- myr ct-GRK2, n = 11, Mean = 4.60 ± 0.605 S.E.M.; Levosulpride Perfusion-myr ct-GRK2, n = 11, Mean = 4.88 ± 0.608 S.E.M.).
ω Theraphotoxin Hg1a, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ω theraphotoxin hg1a/product/Alomone Labs
Average 94 stars, based on 1 article reviews
ω theraphotoxin hg1a - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

Image Search Results


A Graphical abstract illustrating working hypothesis on actions of dopamine tone on spontaneous glutamate release. B Graphical depiction showing experimental paradigm for rotundine (200 nM or 10 μM) or levosulpride perfusions. C Representative mEPSC traces for rotundine (200 nM or 10 μM) or levosulpride perfusions. [Treatment duration: acute perfusion (seconds to minutes)]. D Amplitudes of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions. (Baseline, n = 7, Mean = 15.42 ± 1.36 S.E.M.; 200 nM Rotundine perfusion, n = 7, Mean = 16.46 ± 2.05 S.E.M.; Baseline, n = 13, Mean = 14.34 ± 0.97 S.E.M.; 10 μM Rotundine Perfusion, n = 13, Mean = 14.45 ± 2.33 S.E.M.; Baseline, n = 10, Mean = 16.74 ± 1.61 S.E.M.; 10 μM Levosulpride Perfusion, n = 10, Mean = 16.04 ± 2.30 S.E.M.). E Frequency of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions. (Baseline, n = 7, Mean = 5.72 ± 1.37 S.E.M.; 200 nM Rotundine perfusion, n = 7, Mean = 6.48 ± 1.22 S.E.M.; Baseline, n = 13, Mean = 4.15 ± 1.00 S.E.M.; 10 μM Rotundine Perfusion, n = 13, Mean = 6.48 ± 1.51 S.E.M.; Baseline, n = 10, Mean = 4.23 ± 1.51 S.E.M.; 10 μM Levosulpride Perfusion, n = 10, Mean = 5.96 ± 1.40 S.E.M.). F Graphical abstract illustrating Agatoxin, conotoxin and SNX482 (VGCC cocktail) blocking presynaptic VGCCs. G Graphical depiction showing experimental paradigm for rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail [Treatment duration: acute perfusion (seconds to minutes)]. H Representative mEPSC traces for rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail. I Amplitudes of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail. (Baseline, n = 8, Mean = 15.82 ± 1.32 S.E.M.; 200 nM Rotundine perfusion, n = 8, Mean = 14.99 ± 1.33 S.E.M.; Baseline, n = 11, Mean = 12.74 ± 0.95 S.E.M.; 10 μM Rotundine Perfusion, n = 11, Mean = 12.9 ± 0.68 S.E.M. ; Baseline, n = 16, Mean = 14.91 ± 1.08 S.E.M.; 10 μM Levosulpride Perfusion, n = 16, Mean = 14.86 ± 1.30 S.E.M.). J Frequency of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail. (Baseline, n = 8, Mean = 5.19 ± 0.91 S.E.M.; 200 nM Rotundine perfusion, n = 8, Mean = 4.86 ± 0.60 S.E.M.; Baseline, n = 11, Mean = 3.38 ± 0.72 S.E.M.; 10 μM Rotundine Perfusion, n = 11, Mean = 3.21 ± 0.67 S.E.M. ; Baseline, n = 16, Mean = 4.95 ± 0.97 S.E.M.; 10 μM Levosulpride Perfusion, n = 16, Mean = 5.53 ± 1.33 S.E.M.). K Graphical depiction illustrating myristylation of ct-GRK2 to scavenge Gβγ subunit. L Graphical depiction showing experimental paradigm for Gβγ scavenging. M Representative mEPSC traces for pFUW (control) and myr ct-GRK2 groups at baseline and after levosulpride perfusion [Treatment duration: acute perfusion (seconds to minutes)]. N Amplitudes of mEPSC events in pFUW (control) and myr ct-GRK2 groups at baseline and after levosulpride perfusion. (Baseline-pFUW, n = 9, Mean = 14.66 ± 0.79 S.E.M.; Levosulpride Perfusion-pFUW, n = 9, Mean = 16.62 ± 1.87 S.E.M.; Baseline- myr ct-GRK2, n = 11, Mean = 18.28 ± 1.08 S.E.M.; Levosulpride Perfusion-myr ct-GRK2, n = 11, Mean = 19.3 ± 1.24 S.E.M.). O Frequency of mEPSC events in pFUW (control) and myr ct-GRK2 groups at baseline and after levosulpride perfusion. (Baseline-pFUW, n = 8, Mean = 2.43 ± 0.66 S.E.M.; Levosulpride Perfusion-pFUW, n = 8, Mean = 4.16 ± 1.01 S.E.M.; Baseline- myr ct-GRK2, n = 11, Mean = 4.60 ± 0.605 S.E.M.; Levosulpride Perfusion-myr ct-GRK2, n = 11, Mean = 4.88 ± 0.608 S.E.M.).

Journal: Molecular Psychiatry

Article Title: Dopaminergic tone inhibits spontaneous glutamate release and augments homeostatic synaptic plasticity

doi: 10.1038/s41380-025-03374-6

Figure Lengend Snippet: A Graphical abstract illustrating working hypothesis on actions of dopamine tone on spontaneous glutamate release. B Graphical depiction showing experimental paradigm for rotundine (200 nM or 10 μM) or levosulpride perfusions. C Representative mEPSC traces for rotundine (200 nM or 10 μM) or levosulpride perfusions. [Treatment duration: acute perfusion (seconds to minutes)]. D Amplitudes of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions. (Baseline, n = 7, Mean = 15.42 ± 1.36 S.E.M.; 200 nM Rotundine perfusion, n = 7, Mean = 16.46 ± 2.05 S.E.M.; Baseline, n = 13, Mean = 14.34 ± 0.97 S.E.M.; 10 μM Rotundine Perfusion, n = 13, Mean = 14.45 ± 2.33 S.E.M.; Baseline, n = 10, Mean = 16.74 ± 1.61 S.E.M.; 10 μM Levosulpride Perfusion, n = 10, Mean = 16.04 ± 2.30 S.E.M.). E Frequency of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions. (Baseline, n = 7, Mean = 5.72 ± 1.37 S.E.M.; 200 nM Rotundine perfusion, n = 7, Mean = 6.48 ± 1.22 S.E.M.; Baseline, n = 13, Mean = 4.15 ± 1.00 S.E.M.; 10 μM Rotundine Perfusion, n = 13, Mean = 6.48 ± 1.51 S.E.M.; Baseline, n = 10, Mean = 4.23 ± 1.51 S.E.M.; 10 μM Levosulpride Perfusion, n = 10, Mean = 5.96 ± 1.40 S.E.M.). F Graphical abstract illustrating Agatoxin, conotoxin and SNX482 (VGCC cocktail) blocking presynaptic VGCCs. G Graphical depiction showing experimental paradigm for rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail [Treatment duration: acute perfusion (seconds to minutes)]. H Representative mEPSC traces for rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail. I Amplitudes of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail. (Baseline, n = 8, Mean = 15.82 ± 1.32 S.E.M.; 200 nM Rotundine perfusion, n = 8, Mean = 14.99 ± 1.33 S.E.M.; Baseline, n = 11, Mean = 12.74 ± 0.95 S.E.M.; 10 μM Rotundine Perfusion, n = 11, Mean = 12.9 ± 0.68 S.E.M. ; Baseline, n = 16, Mean = 14.91 ± 1.08 S.E.M.; 10 μM Levosulpride Perfusion, n = 16, Mean = 14.86 ± 1.30 S.E.M.). J Frequency of mEPSC events at baseline and after rotundine (200 nM or 10 μM) or levosulpride perfusions in the presence of VGCC cocktail. (Baseline, n = 8, Mean = 5.19 ± 0.91 S.E.M.; 200 nM Rotundine perfusion, n = 8, Mean = 4.86 ± 0.60 S.E.M.; Baseline, n = 11, Mean = 3.38 ± 0.72 S.E.M.; 10 μM Rotundine Perfusion, n = 11, Mean = 3.21 ± 0.67 S.E.M. ; Baseline, n = 16, Mean = 4.95 ± 0.97 S.E.M.; 10 μM Levosulpride Perfusion, n = 16, Mean = 5.53 ± 1.33 S.E.M.). K Graphical depiction illustrating myristylation of ct-GRK2 to scavenge Gβγ subunit. L Graphical depiction showing experimental paradigm for Gβγ scavenging. M Representative mEPSC traces for pFUW (control) and myr ct-GRK2 groups at baseline and after levosulpride perfusion [Treatment duration: acute perfusion (seconds to minutes)]. N Amplitudes of mEPSC events in pFUW (control) and myr ct-GRK2 groups at baseline and after levosulpride perfusion. (Baseline-pFUW, n = 9, Mean = 14.66 ± 0.79 S.E.M.; Levosulpride Perfusion-pFUW, n = 9, Mean = 16.62 ± 1.87 S.E.M.; Baseline- myr ct-GRK2, n = 11, Mean = 18.28 ± 1.08 S.E.M.; Levosulpride Perfusion-myr ct-GRK2, n = 11, Mean = 19.3 ± 1.24 S.E.M.). O Frequency of mEPSC events in pFUW (control) and myr ct-GRK2 groups at baseline and after levosulpride perfusion. (Baseline-pFUW, n = 8, Mean = 2.43 ± 0.66 S.E.M.; Levosulpride Perfusion-pFUW, n = 8, Mean = 4.16 ± 1.01 S.E.M.; Baseline- myr ct-GRK2, n = 11, Mean = 4.60 ± 0.605 S.E.M.; Levosulpride Perfusion-myr ct-GRK2, n = 11, Mean = 4.88 ± 0.608 S.E.M.).

Article Snippet: VGCC inhibitor cocktail, including Cav2.1 blocker agatoxin, the Cav2.2 blocker conotoxin, and the Cav2.3 blocker SNX482, were obtained from Alamone Labs (Israel).

Techniques: Blocking Assay, Control